+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 2 Actively Recruiting clinical trials

E

Actively Recruiting

Healthy Volunteer

Researchers are evaluating the real-world impact, including safety and test accuracy, of the Galleri4 multi-cancer early detection blood test in Medicare beneficiaries aged 50 years and older. This multi-center prospective cohort study aims to represent the Medicare population and compares usual care with and without the addition of the Galleri test. The study focuses on screening for cancer and assessing how the test affects cancer diagnosis and management over time. Participants are grouped into two arms one receiving the Galleri test alongside usual care, and a second group receiving usual care alone without the Galleri test. The Galleri test involves blood collection and multi-cancer early detection testing with results returned to participants. The study is non-randomized and runs parallel for both groups, observing outcomes over up to three years. During the study, participants are monitored for the incidence of late-stage stage IV cancers. Researchers also track safety by counting invasive procedures prompted by test results, adherence to recommended cancer screenings, and healthcare resources used for cancer diagnostics. The total study duration includes up to three years of follow-up to observe outcomes, with no masking or blinding involved.

Age: 50Years +All GendersPhase Not Applicable
72 locations
C

Actively Recruiting

Researchers are evaluating whether adding gemcitabine to intravesical Bacillus Calmette Guerin BCG treatment improves outcomes for patients with recurrent non-muscle invasive bladder cancer NMIBC after prior BCG therapy. This phase III trial compares the combination of gemcitabine, a chemotherapy drug that blocks DNA production, with standard BCG treatment alone. The study aims to assess differences in cancer recurrence, progression, and safety between these treatments. Participants are randomly assigned to one of two groups. One group receives BCG alone, administered intravesically once weekly for six weeks, followed by additional weekly doses at months 3, 6, and 12 if there is no disease progression or unacceptable side effects. The other group receives a combination of gemcitabine and BCG given intravesically on a specific schedule over 10 weeks, with maintenance doses of both drugs at months 3, 6, and 12 under similar conditions. Both groups undergo bladder biopsies, cystoscopy, TURBT procedures, CT or MRI scans, and blood and urine sample collection throughout the study. After completing treatment, participants are followed every three months for two years, then every six months for up to five years from randomization. Researchers monitor high-grade recurrence-free survival as the primary outcome, along with secondary measures such as cancer-free status at three months, complete response rates, durability of response, time to any bladder cancer recurrence, progression-free survival, cystectomy-free survival, and safety through adverse event rates. The study also collects tumor tissue and biological samples for future research.

Age: 18Years +All GendersPhase 3
60 locations